Prognostic risk factor | Patients (n) | Recurrences (n) | DFS (%) | P value |
Lymph node | ||||
Negative | 115 | 11 | 90.43 | NS |
Positive | 24 | 2 | 91.66 | |
Histology | ||||
Adenocarcinoma | 39 | 2 | 94.87 | NS |
Squamous | 100 | 11 | 89.00 | |
Tumor size (cm) | ||||
0–2 | 60 | 5 | 91.67 | NS |
2.1–3 | 52 | 5 | 90.38 | |
3.1–4 | 22 | 3 | 86.36 | |
NA | 5 | |||
FIGO stage | ||||
IA1 LVSI+ | 5 | 0 | 100.00 | NS |
IA2 | 11 | 0 | 100.00 | |
IB1 | 114 | 12 | 89.47 | |
Other* | 9 | 1 | 88.88 | |
LSVI | ||||
No | 87 | 10 | 88.51 | NS |
Yes | 49 | 3 | 93.87 | |
NA | 3 | |||
Pre-operative brachytherapy | ||||
No | 117 | 11 | 90.59 | NS |
Yes | 22 | 2 | 90.90 | |
Age (years) | ||||
18–40 | 57 | 2 | 96.49 | 0.01 |
41–49 | 44 | 3 | 93.18 | |
≥50 | 38 | 8 | 78.94 |
*Nine patients with pre-operative stage IB1 tumor and stage IB2 or IIB tumor at final pathology.
DFS, disease-free survival;LVSI, lymph-vascular space involvment;NA, not available;NS, non-significant.